Interventions for other risk factors: Tobacco use, physical inactivity, menopause, and homocysteine

American Journal of Kidney Diseases

Volumn 32, Issue 5 SUPPL. 3, 1998, Pages

  Beto, Judith A ^a   Bansal, Vinod K ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Exertion; Homocysteine; Kidney failure; Menopause; Smoking

Indexed keywords

HOMOCYSTEINE;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; HUMAN; MENOPAUSE; PHYSICAL ACTIVITY; REVIEW; RISK FACTOR; SMOKING;

EID: 0031763511     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.1998.v32.pm9820474     Document Type: Review

References (47)

1. Pearson TA, Fuster V: Executive Summary. 27th Bethesda Conference: Matching the Intensity of Risk Factor Management with the Hazard For Coronary Disease Events. September 14-15, 1995. J Am Coll Cardiol 27:961-962, 1995
2. Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch Int Med 154:169-175, 1994
3. Cincirpini PM, McClure JB: Smoking cessation: Recent developments in behavioral and pharamcologic intervention. Oncology 12:249-256, 1998
4. Law M, Tang JL: An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med 155:1933-1941, 1995
5. Goldstein MG: Bupropion sustained release and smoking cessation. J Clin Psychol 59:66-72, 1998 (suppl 4)
6. Held PJ, Port FK, Gaylin DS, Wolfe RA, Levin NW, Blagg CR, Garcia J, Agodoa L: Comorbid conditions and correlations with mortality risk among 3,399 incident hemodialysis patients. Am J Kidney Dis 20:32-38, 1992 (suppl 2)
7. US Renal Data System: USRDS 1997 Annual Report. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1997
8. Rubin HR, Jenckes M, Fink NE, Meyer K, Wu AW, Bass EB, Levin N, Powe NR: Patient's view of dialysis care: Development of a taxonomy and rating of importance of different aspects of care. CHOICE study. Choices for Healthy Outcomes in Caring for ESRD. Am J Kid Dis 30:793-801, 1997
9. Orth SR, Ritz E, Schrier RW: The renal risks of smoking. Kidney Int 51:1669-1677, 1997
10. London GM, Drueke TB: Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 51:1678-1695, 1997
11. Ward MM, Studenski C: Clinical prognostic factors in lupus nephritis: The importance of hypertension and smoking. Arch Intern Med 152:2082-2088, 1992
12. Microalbuminuria Collaborative Study Group of the United Kingdom: Risk factors for development of microalbuminuria in insulin dependent diabetic patients: A cohort study. Br Med J 306:1235-1239, 1993
13. Biesenbach G, Jacko I, Zazgornik J: Similar rate of progression in predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant 9:1097-1102, 1994
14. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end stage renal disease in men. N Engl J Med 334:13-18, 1996
15. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G, Modification of Diet in Renal Disease (MDRD) Study Group: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330:844-847, 1994
16. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J: End stage renal disease in African American and white men: 16 Yr MRFIT findings. JAMA 277:1293-1298, 1997
17. US Department of Health and Human Services: Physical Activity and Health: A Report of the Surgeon General. Atlanta, GA, US Department of Health and Human Services, Centers for Disease Control, NCCDPHP, 1996
18. Judelson DR: Coronary heart disease in women: risk factors and prevention. J Am Med Womens Assoc 49:186-191, 1994
19. Pollack ML, Vincent KR: Resistance training for health. President's Council on Physical Fitness and Sports Research Digest. Washington, DC, Department of Health and Human Services, Series 2, No. 8, December 1996
20. Painter P: The importance of exercise training in rehabilitation of patients with end-stage renal disease. Am J Ed Dis 24:S2-S9, 1994 (suppl)
21. 2 transport during exercise in patients with chronic renal failure. J Clin Inv 97:2092-2100, 1996
22. Paganini EM: In search of a optimal hematocrit level in dialysis patients: Rehabilitation and quality-of-life implications. Am J Kid Dis 24:S10-S16, 1994
23. Kusunoki M, Kimura K, Nakamura M: Effect of hematocrit variations on cerebral blood flow and oxygen transport in ischemic cerebrovascular disease. J Cereb Blood Flow Metab 1:413-417, 1981
24. National Kidney Foundation Dialysis Outcome Quality Initiative: Clinical Practice Guidelines: Management of Anemia. New York, NY, National Kidney Foundation, 1997
25. Fitts SS, Guthrie MR: Six-minute walk by people with chronic renal failure: Assessment of effort by perceived exertion. Am J Phys Med Rehabil 74:54-58, 1995
26. Fitts SS: Physical benefits and challenges of exercise for people with chronic renal disease. J Ren Nutr 7:123-128, 1997
27. Castaneda C, Grossi L, Dwyer J: Potential benefits of resistance exercise training on nutritional status in renal failure. J Ren Nutr 8:2-10, 1998
28. Eidemak I, Haaber AB, Feldt-Rasmussen B, Kanstrup IL, Strandgaard S: Exercise training and the progression of chronic renal failure. Nephron 75:36-40, 1997
29. American Heart Association: AHA Scientific Statement on Cardiovascular Disease in Women. Monograph #71-0119. Dallas TX, American Heart Association, 1996
30. Darling GM, Johns JJ, McCloud PI, Davis SR: Estrogen and progestin compared with simvastatin for heypercholesteroliemia in postmenopausal women. N Engl J Med 337:595-601, 1997
31. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445-1451, 1998
32. Grotz WH, Mundinger FA, Rasenack J, Speidel L, Olschewski M, Exner VM, Schotlmeyer PJ: Bone loss after kidney transplantation: A longitudinal study of 115 graft recipients. Nephr Dial Trans 10:2096-2100, 1995
33. Ginsberg ES, Owen WF, Greenberg LM, Shea BF, Lazarus JM, Walsh BW: Estrogen absorption and metabolism in postmenopausal women with end-stage renal disease. J Clin Endocrinol Metab 81:4414-4417, 1998
34. Joies JA, Bijleveld C, Van Toi A, Gee MJH, Koomans HA: Estrogen replacement during hypoalbuminemia may enhance atherosclerotic risk. J Am Soc Nephrol 8:1870-1876, 1997
35. Selhub J, Rosenburg IH (eds): Present Knowledge in Nutrition. New York, NY, International Life Sciences Institute, 1996, pp 209
36. Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 52:10-20, 1997
37. National Academy of Sciences: Recommended Dietary Allowances (ed 10). Washington, DC, National Academy Press, 1989
38. Tinkle M: Folic acid and food fortification: Implications for the primary care practitioner. Nurse Prac 22:105-114, 1997
39. Mailnow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, Gluckman RA, Block PD, Upson BM: Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 338:1009-1015, 1998
40. Bostom AG, Shemin D, Lapane KL, Nadeau MR, Sutherland P, Chan J, Rozen R, Yoburn D, Jacques PF, Selhub J. Rosenberg IH: Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 123:193-202, 1996
41. The HEMO Study Group, Dwyer JT, Cunniff PJ, Maroni BJ, Kopple JD, Burrowes JD, Powers SN, Cockram DB, Chumlea C, Kusek JW, Makoff R, Goldstein JD, Paranandi L: The Hemodialysis Pilot Study: Nutrition program and participant characteristics at baseline. J Ren Nutr 8:11-20, 1998
42. Rocco MV, Poole D, Poindexter P, Jordan J, Burkart JM: Intake of vitamins and minerals in stable hemodialysis patients as determined by 9-day food records. J Ren Nutr 7:17-24, 1997
43. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis VW: Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97:138-141, 1998
44. Perna AF, Ingrosso D, De Santo NG, Galletti P, Brunone M, Zappia V: Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol 8:1899-1905, 1997
45. Makoff R, Cwyer J, Rocco MV: Folic acid, pyridoxine, cobalamin, and homocysteine and their relationship to cardiovascular disease in end-stage renal disease. J Ren Nutr 6:2-11, 1996
46. Bostom AG, Gohh RY, Beaulien AJ, Nadeau MR, Hume AL, Jacques PF, Selhub J, Rosenberg I: Treatment of hyperhomocysteinemia in renal transplant recipients: A randomized, placebo-controlled trial. Ann Intern Med 127:1089-1092, 1997
47. Bostom AG, Shemin D, Lapane KL, Sutherland P, Nadeau MR, Wilson PWF, Yoburn D, Bausserman L, Tofler G, Jacques PF, Selhub J, Rosenberg IH: Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study. Atherosclerosis 125:91-101, 1996